PD-1 Inhibitors for Hematologic Malignancies
Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.
Clinical Pearls
Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.
- It is unknown as to whether PD-1 inhibitors could be combined with chemotherapy or immunotherapy in hematologic malignancies.
- Nivolumab showed efficacy in classical Hodgkin lymphoma, but it was one of the first studies to analyze the class of drugs into hematologic malignancies.
<<<
Recent Videos
Related Content
